|
|
||||||||||||||
|
|
|||||||||||||||
a Department of
Medical Genetics, University Medical Centre Utrecht, KC.04.084.2, PO
Box 85090, 3508 AB Utrecht, The Netherlands, b Department of
Radiotherapy, University Medical Centre Utrecht, The Netherlands
Correspondence to: Dr van der Luijt, r.b.vanderluijt{at}dmg.azu.nl
Received 16 November
2000;
Accepted for publication 12 December 2000
Germline mutations in either of the two major breast cancer
predisposition genes, BRCA1 and
BRCA2, account for a significant proportion
of hereditary breast/ovarian cancer. Identification of breast cancer
patients carrying mutations of these genes is primarily based on a
positive family history of breast/ovarian cancer or early onset of the
disease or both. In the course of mutation screening of the
BRCA1 and BRCA2
genes in a hospital based series of patients with risk factors for
hereditary breast/ovarian cancer, we identified a germline mutation in
the BRCA2 gene (3034del4) in a patient with
early onset breast cancer and no strong family history of the disease.
Subsequent molecular analysis in her parents showed that neither of
them carried the mutation. Paternity was confirmed using a set of
highly polymorphic markers, showing that the proband carried a de novo
germline mutation in the BRCA2 gene. Interestingly, 3034del4 is a recurrent mutation occurring in a putative
mutation prone region of the BRCA2 gene. Our
study presents the first case in which a de novo germline mutation in
the BRCA2 gene has been identified, and
supports previous results of haplotype studies, confirming that the
3034del4 mutation has multiple independent origins.
This article has been cited by other articles:
![]() |
M Robson, L Scheuer, K Nafa, N Ellis, and K Offit Unique de novo mutation of BRCA2 in a woman with early onset breast cancer J. Med. Genet., February 1, 2002; 39(2): 126 - 128. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |